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Aims.We aimed to summarize available lines of evidence about intraoperative andpostoperative donor outcomes following robotic-
assisted laparoscopic donor nephrectomy (RALDN) as well as outcomes of graft and recipients. Methods. A systematic review of
PubMed/Medline, ISI Web of Knowledge, and Scopus databases was performed in May 2018. The following search terms were
combined: nephrectomy, robotic, and living donor.We included full papers thatmet the following criteria: original research; English
language; human studies; enrolling patients undergoing RALDN. Results. Eighteen studies involving 910 patients were included in
the final analysis. Mean overall operative and warm ischemia times ranged from 139 to 306 minutes and from 1.5 to 5.8 minutes,
respectively. Mean estimated blood loss varied from 30 to 146 mL and the incidence of intraoperative complications ranged from
0% to 6.7%. Conversion rate varied from 0% to 5%.Themean hospital length of stay varied from 1 to 5.8 days and incidence of early
postoperative complications varied from 0% to 15.7%. No donor mortality was observed. The incidence of delayed graft function
was reported in 7 cases.The one- and 10-year graft loss rates were 1% and 22%, respectively.Conclusions. Based on preliminary data,
RALDN appears as a safe and effective procedure.
1. Introduction
Renal transplantation is the treatment of choice for suitable
patients with end-stage renal disease (ESRD) as it provides
better outcomes in terms of life expectancy and quality
of life than dialysis [1]. Kidney transplants from living
donors confer advantages in terms of graft function and
survival if we compared transplants from deceased donors
[2]. Indeed, the elective nature of living donor transplantation
offers the opportunity to have good quality grafts and to
perform the procedure when the recipient is in an optimal
clinical status. The main obstacle to living donation is
the exposure of a healthy subject to the risks of a major
surgical intervention. Therefore, efforts have been made to
reduce complications and postoperative pain, achieve faster
recovery, and minimize the surgical incisions. Laparoscopic
donor nephrectomy (LDN) was first introduced in 1995
and is currently accepted as the gold standard for kidney
procurement from living donors. This minimally invasive
procedure has greatly enhanced living donation rates and in
2001 the number of living donors exceeded the number of
cadaver donors [3]. To date, living donors account for most
of the kidney donor pool in Western countries [4]. However,
deceased donors still represent about 67.6% of transplanted
kidneys [4]. In 2000, the US Food and Drug Administration
approved the da Vinci Surgical System (Intuitive Surgical
Inc.), a system that combines robotic techniques and com-
puter imaging to enable microsurgery in a laparoscopic
environment [5]. Advantages of the da Vinci Surgical System
include the precision and instinctive movements of open
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surgery, an optimal ergonomic environment for the surgeon,
and a 3-dimensional vision system that restores the hand-eye
coordination lost in laparoscopic procedures [5–7]. The first
worldwide robotic assisted laparoscopic donor nephrectomy
(RALDN) was performed successfully at the University of
Illinois at Chicago in 2000 byHorgan et al. [3]. Since then, the
adoption of RALDN has increased worldwide and evidence
about this procedure has slowly increased. The aim of the
present review was to summarize available lines of evidence
about intra- and postoperative donor outcomes following
RALDN as well as outcomes of grafts and recipients.
2. Materials and Methods
We performed a systematic review using the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
Statement as a guideline in the development of the study
protocol [19]. In May 2018 we used the National Library of
Medicine PubMed search engine, the Scopus database, and
the ISI Web of Knowledge official website to search for all
published studies evaluating lines of evidence about donor
and recipient outcomes following RALDN. The following
search terms were combined: nephrectomy, robotic, and
living donor.We included publications that met the following
criteria: reporting original clinical studies; English language.
Reference lists in relevant articles and reviews were also
screened for additional studies. Abstracts (with no subse-
quent full-text publications) and unpublished studies were
not considered. The quality of the randomized controlled
trials was assessed using the Jadad score [20]. The following
data were extracted from included studies: first author,
year of publication, study design, sample size, study period,
donors’ age and sex, side of nephrectomy, surgical technique,
control group, operative time (OT), console time (CT), warm
ischemia time (WIT), estimated blood loss (EBL), conversion
rate (CR), incidence, type and grade of intraoperative and
postoperative complications, length of hospital stay (LOS),
hemoglobin decrease, transfusion rate (TR), postoperative
pain, duration of follow-up, last estimated glomerular filtra-
tion rate (eGFR), last creatinine, incidence of delayed graft
function (DGF), duration of recipients’ follow-up, recipients’
last eGFR, recipients’ last creatinine, graft survival, and
recipients’ complications.
3. Results
The search strategy revealed a total of 40 results. Screening
of the titles and abstracts revealed 22 papers eligible for
inclusion. Further assessment of eligibility, based on full-text
papers, led to the exclusion of 4 papers. Finally, 18 studies
involving a total of 910 patients who underwent RALDN
from 2000 to 2018 were included in final analysis [2–18]
(Figure 1). Specifically, 8 studies (44.4%) were retrospective
observational, 4 (22.2%) were prospective observational, 1
(5.5%) was a randomized controlled trial, and 5 (27.7%) were
case reports. The only randomized controlled trial was of
low methodological quality (Jadad score =2). Eight studies
(44.4%) had a control arm. The characteristics of the studies
included are summarized in Table 1.
3.1. Intraoperative Outcomes. Table 2 summarizes RALDN-
related intraoperative outcomes. Left kidneys were procured
in 93.85% (n=854) of the donors.
3.2. Operative Times. Mean OT and mean CT ranged from
139 to 306 minutes and from 82 to 120 minutes, respectively.
Three comparative studies found mean OT to be significantly
longer in RALDN series with respect to LDN [4, 13, 16]. Mean
OT of RALDN was also significantly longer than open donor
nephrectomy (ODN) and hand-assisted retroperitoneoscopic
donor nephrectomy (HARP) [4, 7, 13]. The relationship
between vascular anatomy andOT is controversial. Gorodner
et al. found that OT was significantly longer in patients
with vascular anomalies with respect to those with normal
vascular anatomy [8]. Similarly, Horgan et al. found OT to
be significantly longer in patients with multiple renal arteries
with respect to patients with normal anatomy [3]. Unlike
previous authors, Janky et al. found no significant differences
in terms of OT between donors with simple and complex
vascular anatomy [13]. Interestingly, mean OT has been
reported to significantly decrease with experience [3, 13]. In
their study, Horgan et al. found a significant decrease in OT
when their series was divided into three periods and the first
74 cases (201 minutes) were used for comparison with those
in the second period (cases 75-144, 129 minutes) and third
period (cases 145-214, 103 minutes) [3]. Similarly, Janki et al.
foundmeanOTof RALDNprocedures 1-19 to be significantly
longer than RALDN procedures 40-59 (median OT of 240
and 172.5 minutes, respectively) [13]. In the study by Yang
et al., the OT of RALDN approached that of LDN with each
subsequent procedure over the course of the robotic cases and
the standard OT of LDN was reached at the 22nd case [16].
3.3. Warm Ischemia Time. WIT ranged from <1.5 to 5.8
minutes. The impact of surgical technique on WIT is contro-
versial. Two comparative studies found significantly longer
WIT in patients undergoing RALDN with respect to those
undergoing LDN [12, 16]. Two other comparative studies
found WIT to be significantly longer in patients undergoing
ODN and HARP [7, 13]. Unlike previous authors, Liu et
al. and Janki et al. failed to find significant differences in
terms of WIT between RALDN and LDN [1, 13]. The impact
of vascular anatomy on WIT is controversial. Gorodner et
al. found WIT to be significantly lower in patients with
normal vascular anatomy with respect to patients with
vascular anomalies [8]. Horgan et al. failed to find significant
differences between patients with multiple renal arteries and
patients with normal vascular anatomy in terms of WIT [3].
3.4. Intraoperative Complications. The incidence of intraop-
erative complications ranged from 0% to 6.7%. Bleeding
was the most frequent complication and was reported in
11 patients (1.2%). Mean EBL varied from 30 mL to 146
mL. Janki et al. found EBL to be significantly lower in
patients undergoing RALDN compared to HARP and LDN
[13]. Serrano et al. found significantly lower EBL in patients
undergoing RALDN compared to ODN, hand assisted LDN
(HALDN) and LDN (80 mL, 296 mL, 91 mL, and 130
mL, respectively) with intraoperative transfusion rate of
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Figure 1: Flow diagram of the systematic review.
0%, 0.3%, 0.5%, and 3% in RALDN, HALDN, LDN, and
ODN, respectively (p<0.05) [4]. Other authors failed to find
statistically significant differences between RALDN and LDN
in terms of EBL [10, 13, 16]. One study found EBL to be
significantly higher in patients with vascular abnormalities
(107 mL vs 72 mL, p<0.05) [3].
3.5. Conversion Rates. CR varied from 0% to 5%. Overall, 14
cases (1.5%) of open conversion were reported. The reasons
for conversion included inability to control bleeding from
lumbar veins, bleeding of the stump of the renal artery, failure
of the stapling device on the renal artery stump, and bleeding
from renal vein laceration [3–5, 8, 10, 13]. In the study by
Gorodner et al., all conversions occurred during the initial
100 cases [10]. Similarly, all the 4 conversions reported by
Horgan et al. occurred in the first 74 cases [3].
3.6. Early (< 30 Days) Postoperative Donors’ Outcomes.
RALDN-related early postoperative donors’ outcomes are
summarized in Table 2.
3.7. Hospital Length of Stay. The mean hospital LOS ranged
from 1 to 5.8 days. One comparative study found mean hos-
pital LOS to be significantly shorter after RALDN compared
to LDN [12]. Two other comparative studies found mean
hospital LOS to be significantly shorter after RALDN com-
pared to ODN [4, 7]. Five studies failed to find statistically
significant differences between RALDN and LDN [1, 4, 10,
13, 16]. Cohen et al. found that mean LOS decreased with
increasing RALDN experience [5]. Indeed, mean hospital
LOS was 1.5 days, 2.3 days, and 2.0 days in the last 80
RALDN procedures, in the initial 20 RALDN, and in the
last HALDN, respectively, with 20% of donors undergoing
HALDN still in the hospital on postoperative day 3 compared
to only 3.7% of donors in the last 80 RALDN procedures
[5].
3.8. Postoperative Complications. The incidence of early post-
operative complications ranged from 0% to 15.7%. In their
study,Horgan et al. found that the postoperative complication
rate dropped from 24% in the first 74 cases to a steady rate of
7% in the last part of their cohort [3]. Only 4 studies graded
complications according to the Clavien Classification system
by showing a high prevalence ofGrades I and II complications
[12, 13, 15, 16]. Comparative studies failed to find statistically
significant differences between RALDN, ODN, LDN, and
HARP in terms of postoperative complications [12, 13, 16]. No
donor mortality was observed.
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3.9. Postoperative Pain. Postoperative pain was investigated
by three studies [2, 11, 12]. In the study by Bhattu et al., visual
analogue scale scores for postoperative pain at 6, 24, and
48 hours as well as analgesic requirement were significantly
lower after RALDN compared to LDN [12].
3.10. Late (>30 Days) Postoperative Donor Outcomes. Late
postoperative donor outcomes were investigated by four
studies [4, 9, 13, 16]. Mean follow-up ranged from 1.5 to
120 months (Table 2). Janky et al. failed to find statistically
significant differences in terms of serum creatinine and eGFR
at 3 months’ follow-up after RALDN or LDN [13]. Yang et
al. found similar results at one-year follow-up [16]. Serrano
et al. found the incidence of ESRD to be close to 0% for
all donors at 10 years’ follow-up and this outcome was not
influenced by surgical procedure (ODN, LDN, HA-LDN,
and RALDN) [4]. The incidence of late complications was
similar between RALDN and LND at one-year follow-up
[16].
3.11. Recipient and Graft Outcomes. Table 3 summarizes
results from studies evaluating recipient and graft outcomes
relative to donors undergoing RALDN. Most of grafts
functioned immediately after transplantation and DGF was
reported in 7 cases. The incidence of DGF was not influenced
by the surgical procedure adopted to procure the kidney
(RALDN or LDN) [1]. Janki et al. failed to find significant
differences in graft or recipient survival between RALDN
and LDN as well as between RALDN and HARP at three-
month follow-up [13]. In the study by Renoult et al. no
significant differences emerged between recipients of donors
undergoing RALDN and ODN [7]. Similarly, Yang et al.
found no significant differences in terms of recipients’ and
grafts’ outcomes at one-year follow-up regardless of the donor
procedure [16]. In detail, there were no cases of graft failure
or DGF in recipients of donors undergoing RALDN while
there were three cases of graft failure and one case of DGF
in patients who received kidneys from donors undergoing
LDN [16]. eGFR was similar between recipients of donors
undergoing RALDN and LDN at one-year follow-up [16].
In the study by Bhattu et al., eGFR at 7 days and at 1, 3,
6, and 9 months were similar among recipients of donors
undergoing RALDN and LDN and no graft loss was observed
in the two groups [12]. Indeed, each of the transplanted
kidneys functioned correctly following surgery and none
of the recipients required posttransplant dialysis [7]. Based
on the measurement of the creatinine reduction ratio from
posttransplantation day 1 to day 2, graft function improved
more rapidly in the first two days after transplantation in
the RALDN group with respect to ODN (42.6% vs 32.6%,
p=0.01) and the mean estimated creatinine clearances at day
5 showed no differences between the two groups [7]. In
the study by Serrano et al. the one-year graft loss rate for
recipients whose living donor was in the ODN cohort was
9% versus the 2% in HA-LDN, 2% in P-LND, and 1% in
RALDN cohorts [4]. The 10-year graft loss rate for recipients
whose living donor was in the ODN, HA-LDN, P-LDN, and
RALDN cohort was 27%, 23%, 20%, and 22%, respectively
[4].
4. Discussion
Kidney transplant represents a common surgical interven-
tion, with many cases performed yearly around the world
[21, 22].The procedure offers advantages over chronic dialysis
in terms of quality of life and life expectancy. The number of
patients requiring kidney transplantation increases with time
and an improvement of the donation experience is strongly
advocated [5, 16]. Unlike most surgical procedures, live
donor nephrectomy is a unique, elective procedure, where
a subject undergoes surgery for the sole benefit of another
[16].Therefore, it is of great importance to keep themorbidity
and mortality of the procedure as low as possible [23].
Moreover, efforts should be made to procure the kidneys in
optimal conditions for transplantation [23]. For many years,
live donor nephrectomy was performed only with an open
surgical approach and thereby many potential donors were
reluctant to donate due to the morbidity associated with the
procedure [23]. In 1995, Ratner et al. performed the first LDN
at Johns Hopkins University of Baltimore [24]. LDN demon-
strated several improvements over ODN such as decreased
postoperative pain, decreased hospital LOS, faster recovery,
and reduced perioperative blood loss [16]. Due to these
advantages, LDNhas become the standard of care and several
modifications have been made to improve the technique [16].
The introduction of precise surgical robotic systems, like the
da Vinci system, has expanded surgeons’ ability to complete
complex surgical tasks in a minimally invasive fashion. Some
authors hypothesized that robotic assistance could result in
a shorter and simpler learning curve for the procurement
of kidneys from living donors and that it could enable an
easier and more efficient management of complications [15].
By decreasing the learning curve for difficult surgical tasks,
surgical robots may also expand the number of available
surgeons for complex interventions as well as allow newer
surgeons to quickly master these procedures [16]. In 2000,
Horgan et al. performed for the first time a RALDN [25].
Since then, it has been adopted by several Institutions world-
wide and the amount of evidence has progressively increased.
To date, RALDN represents an evolving field. A new surgical
technique should be compared against the gold standard.
OT, EBL, incidence of complications, and conversion to
open surgery are relevant intraoperative outcomes for most
laparoscopic and robotic surgical procedures.TheOTof LDN
has been reported to range from 183 to 340 minutes [23].
Some authors have reported significantly longer OT with
RALDN compared to LDN. Yang et al. hypothesized that
the longer OT could be a result of their cautious, slower
approach with RALDN due to their initial unfamiliarity with
the procedure [16]. Interestingly, it has been demonstrated
that OT associated with RALDN significantly decreases with
experience and approaches the mean OT of LDN after few
cases. Bleeding represents the most frequent intraoperative
complication. However, two of the most recent comparative
studies found EBL to be significantly lower during RALDN
compared to LDN [4, 13]. Other studies found no significant
difference between the two techniques in terms of EBL. It has
been hypothesized that robot assistance may allow surgeons
to dissect rapidly and efficiently and to control problematic
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bleedings more easily [7]. The reported frequency of open
conversion during LDN ranges from 0% to 13% [4, 23]. The
CR reported in the overall RALDN population analyzed in
the present review is within the published ranges for LDN.
Interestingly, most conversions occurred during the early
phase of the learning curve. Giacomoni et al. hypothesized
that the use of the robotic assistance can help to avoid the
open conversion in cases of acute bleeding as it may facilitate
the repair of vascular lesions [15]. WIT has traditionally
represented a major concern during donor nephrectomy as it
has been thought that any increase in this parameter would
have translated into a poor graft function [23]. However,
this notion has been disproved by various studies. WIT
during LDN ranges between 95 and 300 seconds. Globally,
WIT reported during RALDN is within published ranges for
LDN. Some authors reported significantly longer WIT with
RALDN compared to LDN probably related to the extraction
that is performed by a second attending surgeon [16]. As
RALDN is a relatively new procedure, the learning curve is a
possible cause of differences observed in some intraoperative
outcomes including OT and WIT [16]. Major advantages of
RALDN over LDN are in the early postoperative period.
Indeed, RALDN is characterized by lower postoperative pain
and shorter hospital LOS. Bhattu et al. hypothesized that
one of the possible reasons for less pain following robotic
surgery is robotic arms, which are pivoted around the port
site and moved at fixed remote center [12]. Consequently,
there is less leverage and lesser pressure at port sites with
subsequent lesser trauma to abdominal wall tissues around
the port [12]. Some authors attributed the short LOS in the
robotic-assisted program to reduced manipulation of the
peritoneum, better identification of dissection planes, and
limited energy use from cauterization leading to minimal
inflammation and pain [5, 12]. Shorter LOS makes the
RALDN procedure more convenient for the donor by allow-
ing him to return as soon as possible to routine activities [5].
In a systematic review and meta-analysis of published work
relative to 32,038 nephrectomies following different surgical
techniques, Kortram et al. reported a global complication
rate of 9.3% with complication rate after LDN being 23% [15,
26]. The present review demonstrates that the incidence of
early postoperative complications is similar between RALDN
and LDN. Interestingly, most of the complications occurred
at the beginning of the learning curve. Unfortunately, the
incidence of late postoperative complications was largely
underinvestigated. Graft function and survival as well as
recipient outcomes are of great importance when considering
kidney donor procedures. Available lines of evidence demon-
strate that RALDNdoes not adversely affect allograft function
and survival. Although OT and WIT are longer in many
RALDN experiences with respect to LDN, this seems not
to translate into poorer graft function or recipient outcomes
[16].The incidences of DGF, graft function, and survival were
similar between recipients whose living donor was in the
RALDN and LDN cohorts in many studies. These data are
coherent with the evidence that WIT up to 720 seconds do
not correlate with graft function [16, 27]. Major limitations
of current robotic systems are high costs and lack of haptic
feedback [15, 28, 29]. However, daily use of the robot may
reduce robotic costs mainly in a high-volume institute if the
system is made available to multidisciplinary surgical teams
[15]. The adoption of single-site robotic platforms has been
described by some authors [17]. Early experience showed
the safety of this approach but found that the technology
added cost and complexity without tangible benefits [17].
Although the single port technology may decrease surgical
invasiveness, its widespread adoption in the clinical prac-
tice will require the development of dedicated articulating
instruments, energy, and stapling devices [17]. Potential
limits of available literature must be acknowledged: available
studies are few, often of low methodological quality, and
with short follow-up. They enroll a small number of patients
and often populations and surgical technique employed are
different. Moreover, the quality of life after RALDN remains
largely underinvestigated. Finally, the outcomes in specific
populations, such as older living donors, need to be addressed
[30, 31].
5. Conclusions
Available studies point out the feasibility and safety of
RALDN. Although OT and WIT have been reported to be
longer with respect to LDN in some studies, a progressive
improvement with experience is evident. The procedure can
provide potential advantages in terms of EBL, hospital LOS,
and postoperative pain with respect to LDN. Graft and
recipient outcomes are comparable to LDN. However, the
technique is still in its infancy in many Institutions and avail-
able lines of evidence are still of poor quality. Consequently,
these results should be interpreted with caution and role of
RALDN needs further investigations.
Conflicts of Interest
Authors have no conflicts of interest to declare.
Authors’ Contributions
Massimiliano Creta and Armando Calogero contributed
equally to this work.
References
[1] X. S. Liu, H. W. Narins, W. R. Maley, A. M. Frank, and
C. D. Lallas, “Robotic-assistance does not enhance standard
laparoscopic technique for right-sided donor nephrectomy,”
Journal of the Society of Laparoendoscopic Surgeons, vol. 16, no.
2, pp. 202–207, 2012.
[2] C. A. Galvani, U. Garza, M. Leeds et al., “Single-incision
robotic-assisted living donor nephrectomy: Case report and
description of surgical technique,”Transplant International, vol.
25, no. 8, pp. e89–e92, 2012.
[3] S. Horgan, C. Galvani, M. V. Gorodner et al., “Effect of robotic
assistance on the “learning curve” for laparoscopic hand-
assisted donor nephrectomy,” Surgical Endoscopy, vol. 21, no. 9,
pp. 1512–1517, 2007.
[4] O. K. Serrano, V. Kirchner, A. Bangdiwala et al., “Evolution
of Living Donor Nephrectomy at a Single Center: Long-Term
10 BioMed Research International
Outcomes with 4 Different Techniques in Greater Than 4000
Donors over 50 Years,”Transplantation, vol. 100, no. 6, pp. 1299–
1305, 2016.
[5] A. J. Cohen, D. S. Williams, H. Bohorquez et al., “Robotic-
assisted laparoscopic donor nephrectomy: Decreasing length of
stay,”The Ochsner Journal, vol. 15, no. 1, pp. 19–24, 2015.
[6] J. Hubert, E. Renoult, E. Mourey, L. Frimat, L. Cormier, and
M. Kessler, “Complete robotic-assistance during laparoscopic
living donor nephrectomies: An evaluation of 38 procedures at
a single site,” International Journal of Urology, vol. 14, no. 11, pp.
986–989, 2007.
[7] E. Renoult, J. Hubert, M. Ladrie`re et al., “Robot-assisted
laparoscopic and open live-donor nephrectomy: A comparison
of donormorbidity and early renal allograftoutcomes,”Nephrol-
ogy Dialysis Transplantation , vol. 21, no. 2, pp. 472–477, 2006.
[8] V. Gorodner, S. Horgan, C. Galvani et al., “Routine left robotic-
assisted laparoscopic donor nephrectomy is safe and effective
regardless of the presence of vascular anomalies,” Transplant
International, vol. 19, no. 8, pp. 636–640, 2006.
[9] A. Pietrabissa, M. Abelli, A. Spinillo et al., “Robotic-assisted
laparoscopic donor nephrectomy with transvaginal extraction
of the kidney,” American Journal of Transplantation, vol. 10, no.
12, pp. 2708–2711, 2010.
[10] S. Geffner, Z. Klaassen, M. Tichauer, R. S. Chamberlain, and P.
R. Paragi, “Robotic-assisted laparoscopic donor nephrectomies:
Early experience and review of the literature,” Journal of Robotic
Surgery, vol. 5, no. 2, pp. 115–120, 2011.
[11] J. H. Kaouk, A. Khalifeh, H. Laydner et al., “Transvaginal hybrid
natural orifice transluminal surgery robotic donor nephrec-
tomy: First clinical application,”Urology, vol. 80, no. 6, pp. 1171–
1175, 2012.
[12] A. S. Bhattu, A. Ganpule, R. B. Sabnis, V. Murali, S. Mishra,
andM.Desai, “Robot-assisted laparoscopic donor nephrectomy
vs standard laparoscopic donor nephrectomy: A prospective
randomized comparative study,” Journal of Endourology, vol. 29,
no. 12, pp. 1334–1340, 2015.
[13] S. Janki, K. W. J. Klop, S. M. Hagen et al., “Robotic surgery
rapidly and successfully implemented in a high volume laparo-
scopic center on living kidney donation,” The International
Journal of Medical Robotics and Computer Assisted Surgery, vol.
13, no. 2, 2017.
[14] R. Gonzalez-Heredia, R. Garcia-Roca, and E. Benedetti, “Hand-
assisted robotic right donor nephrectomy in patient with total
situs inversus: A case report,” International Journal of Surgery
Case Reports, vol. 23, pp. 44–46, 2016.
[15] A. Giacomoni, L. Centonze, S. Di Sandro et al., “Robot-
assisted harvesting of kidneys for transplantation and global
complications for the donor,” Transplantation Proceedings, vol.
49, no. 4, pp. 632–637, 2017.
[16] A. Yang, N. Barman, E. Chin et al., “Robotic-assisted vs.
laparoscopic donor nephrectomy: a retrospective comparison
of perioperative course and postoperative outcome after 1 year,”
Journal of Robotic Surgery, vol. 12, no. 2, pp. 343–350, 2018.
[17] J. C. LaMattina, J. Alvarez-Casas, I. Lu et al., “Robotic-assisted
single-port donor nephrectomy using the da Vinci single-site
platform,” Journal of Surgical Research, vol. 222, pp. 34–38, 2018.
[18] N. Barman andM. Palese, “Robotic-assisted laparoscopic donor
nephrectomy of patient with nutcracker phenomenon,” Experi-
mental and Clinical Transplantation, vol. 16, no. 2, pp. 212–215,
2018.
[19] D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred
reporting items for systematic reviews and meta-analyses: the
PRISMA statement,” British Medical Journal, vol. 339, article
b2535, 2009.
[20] A. R. Jadad, Randomised controlled trials, BMJ Publishing
Group, London, UK, 1998.
[21] M. Santangelo, P. de Rosa, S. Spiezia et al., “Healing of surgical
incision in kidney transplantation: a single transplant center’s
experience,” Transplantation Proceedings, vol. 38, no. 4, pp.
1044–1046, 2006.
[22] M. Santangelo, M. Clemente, S. Spiezia et al., “Wound com-
plications after kidney transplantation in nondiabetic patients,”
Transplantation Proceedings, vol. 41, no. 4, pp. 1221–1223, 2009.
[23] N. Gupta, P. Raina, and A. Kumar, “Laparoscopic donor neph-
rectomy,” Journal of Mininal Access Surgery, vol. 1, no. 4, pp. 155–
164, 2005.
[24] L. E. Ratner, L. J. Ciseck, R. G. Moore, F. G. Cigarroa, H.
S. Kaufman, and L. R. Kavoussi, “Laparoscopic live donor
nephrectomy,” Transplantation, vol. 60, no. 9, pp. 1047–1049,
1995.
[25] S. Horgan, D. Vanuno, P. Sileri, L. Cicalese, and E. Benedetti,
“Robotic-assisted laparoscopic donor nephrectomy for kidney
transplantation,” Transplantation, vol. 73, no. 9, pp. 1474–1479,
2002.
[26] K. Kortram, J. N. M. Ijzermans, and F. J. M. F. Dor, “Peri-
operative events and complications in minimally invasive live
donor nephrectomy: a systematic review and meta-analysis,”
Transplantation, vol. 100, no. 11, pp. 2264–2275, 2016.
[27] M. M. Buzdon, E. Cho, S. C. Jacobs, B. Jarrell, and J. L.
Flowers, “Warm ischemia time does not correlatewith recipient
graft function in laparoscopic donor nephrectomy,” Surgical
Endoscopy, vol. 17, no. 5, pp. 746–749, 2003.
[28] A. Ferrarese, G. Pozzi, F. Borghi et al., “Malfunctions of robotic
system in surgery: Role and responsibility of surgeon in legal
point of view,” Open Medicine, vol. 11, no. 1, pp. 286–291, 2016.
[29] A. Ferrarese, G. Pozzi, F. Borghi et al., “Informed consent in
robotic surgery:Quality of information andpatient perception,”
Open Medicine (Poland), vol. 11, no. 1, pp. 279–285, 2016.
[30] T. Song, L. Fu, Z. Rao et al., “Kidneys from older living donors
provide excellent short and intermediate outcomes-a single
China center’s experience,” Transplantation, vol. 99, no. 8, pp.
e81–e88, 2015.
[31] C. Grifasi, A. Calogero, A. Esposito, and C. Dodaro, “Periop-
erative care of elderly outpatients. A review,” Annali Italiani di
Chirurgia, vol. 86, no. 2, pp. 100–105, 2015.
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
